Vasundhara Rasayans Ltd
Incorporated in 1987, Vasundhara Rasayans Ltd manufacturing and exporter Antacids therapeutic category of Active Pharm Ingredients
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
17 Jun - Vasundhara Rasayans confirms it is not a 'Large Corporate' per SEBI's debt issuance framework.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Annual Secretarial Compliance Report confirms full SEBI compliance for FY 2024-25, no violations or actions.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 May - Newspaper Advertisement pertaining to the audited financial results of the Company for the Quarter and year ended on 31.03.2025
-
Financial Results For The Quarter And Year Ended As On 31.03.2025.
28 May - Audited financial results for FY ended March 31, 2025 approved; unmodified audit opinion received.
-
Board Meeting Outcome for Board Meeting Outcome For The Outcome Of Board Meeting And Submission Of Financial Results For The Quaarter And Year Ended As On 31.03.2025
28 May - Audited financial results for FY ended March 31, 2025 approved; unmodified audit opinion received.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
Company offers wide range antacid therapeutic category of API andis also having an API intermediate plant to handle organic product